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was still present when starting PT after incomplete resection 
or biopsy only. Treatment sites were head and neck/base of 
skull (n=59), pelvis (n=19), spinal/paraspinal area (n=23). The 
median PT dose administered was 55.8 Gy (45.0 - 74.0 Gy) 
with a median number of 31 fractions (range 25-41). Mixed 
beam technique was delivered in 2 patients only. In 53.5% of 
the patients (48 children, 6 adults) concomitant 
chemotherapy was applied. Treatment related side-effects 
were classified according to CTCAE V4.0 grading system and 
were assessed weekly during PT and in all follow-up visits. 
 
Results: Median follow-up after first diagnosis was 10.6 
months (range 3.3 months to 10.5 years). During PT no or 
only mild to moderate (grade 1 to 2) additional acute side-
effects were documented in the majority of patients (n=79); 
predominantly erythema, alopecia, mucositis, fatigue, pain, 
and hematotoxicities when compared to baseline. In 28 
children, additional grade 3 side-effects occurred during PT; 
aplasia (n=10; all receiving concomitant chemotherapy), 
mucositis (n=7; all receiving concomitant chemotherapy), 
general disorder (n=5), nausea, skin ulceration, headache, 
diplopia, anorexia, and arthralgia (each n=1). Additional 
grade 4 side-effects during PT were only seen in one patient 
for blood/bone marrow (n=1) while receiving concomitant 
chemotherapy. So far, nine patients failed due to systemic 
(n=6) or local (n=3) recurrence or progression. Five of these 
patients died due to disease. 
In 73 patients, information on early-late effects after at least 
3 months is available. In this group one new grade 3 side 
effect (fatigue) revealed and one new hematotoxicity was 
documented while receiving concomitant chemotherapy. No 
grade 4 or 5 toxicity was observed. 
 
Conclusion: Current prospective and standardized data in 
sarcomatous tumor patients from WPE registry suggest good 
feasibility of the treatment even when high doses are 
administered at critical sites and sensitive tissues. However, 
longer FU is needed to understand the clinical benefit both in 
terms of late side effects and local control. 
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Purpose or Objective: Uterine Sarcomas represent 3-7% of 
Uterine Carcinomas. Stage, Grade, Histology and Lymph 
Nodes are important prognostic factors. Non metastatic 
patients had reduced local-regional failure (LRF) with 
radiotherapy. We evaluated 23 patients treated with 3D-
Conformal Irradiation (3D-CRT), Brachytherapy (BT), and 
Chemotherapy. 
 
Material and Methods: 23 PATIENTS WITH Stage I – III (FIGO 
2009) were analysed after TAH/BSO and peritoneal washings 
sampling. 15 patients with Malignant Mullerian Tumors 
(MMT), 2 Leiomyosarcomas (LMS), 1 grade 3 Stromal Sarcoma 
received adjuvant concurrent chemoradiation (CCRT). 5 
patients (3 MMT and 2 LMS) were treated for local relapse 
(Pelvic and/or Nodal involvement). 3D-CRT was given with a 
18MV Linac (59.40Gy in 1.8Gy/Fr, 5d/w). All patients 
received 1 MDR intracavitary insertion with 15Gy at the 
surface of the applicator. Concomitant Caelyx (12mg/m2) 
and CDDP (25mg/m2) were given the 1st and 4th day of each 
week respectively for a total of 6.6 weeks. In addition, 
Caelyx (20mg total) or CDDP (50mg total) were given 
simultaneously with MDR Brachytherapy depending on the 
hematologic toxicity of each patient.The above drugs were 
used as adjuvant treatment in every case for 4-6 Cycles after 
CCRT completion.  
 
Results: patients were deemed eligible for the study. The 
median age was 66 years. For the adjuvant treatment, 
13(72%) and 5(27%) patients were Stage I and II respectively. 
There have been 3/18(17%) locoregional relapses combined 
with lung metastases in 2 of them (LMS patients who died at 
24 and 26 months). Of the 5 patients with documented LRFs 2 
patients died at 24 and 31 months with disease progression. 
Overall 16/18(88%) with stage I/II and 3/5(60%) wth stage III 
are alive and disease free at a median follow up of 3 years 
(range 2-8 years). Leucopenia and CCRT enteritis/colitis were 
the most commonly reported toxicities. 
 
Conclusion: CCRT given for Uterine Sarcoma patients as 
adjuvant treatment or at LRF is a tolerable and effective 
treatment which needs verification in large phase II/III trials. 
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Purpose or Objective: Primary cardiac sarcomas are 
extremely rare and unfavourable malignancies. Surgery, 
although technically challenging, remains the mainstay of 
treatment. Only few data are available on the use of 
chemotherapy (CT) and radiotherapy (RT) for advanced 
disease. Basing on experiences with combined surgery, RT 
and CT in extremities sarcomas, we explored the feasibility 
of this multimodality approach in cardiac sarcomas. An 
update on tolerance and safety of treatment with focus on 
RT program is reported. 
 
Material and Methods: A retrospective analysis of a 
consecutive series of patients (pts) with unresectable disease 
referred to our Institute is reported. After oncologic-
cardiologic evaluation, anthracyclin-based CT was 
considered, followed by RT. IMRT-IGRT (Helical Tomotherapy) 
was used for more accurate tumor-conformal treatment 
while sparing the no-tumor-bearing surrounding heart tissue 
and to reduce the risk of radiation-induced heart disease 
(RIHD). Echocardiography was used in the treatment planning 
for organ motion and target-volume margin definition. Full-
dose RT with 45 Gy/25 frs with SIB up to 54 Gy was planned. 
Individualised dose constraints to left and right ventricles 
were included. 
 
Results: Between June 1998 and March 2013, 17 consecutive 
pts (M/F: 11/6, median age: 53yrs (25-72) with M0 cardiac 
sarcoma were referred to our Institute. Tumor location was 
right atrium in 8 pts, left atrium in 6, left ventricle in 2, 
pulmonary artery in 1pt; most common histologic type was 
angiosarcoma (62%). 8 pts had unresectable disease and 9 
had complete resection. 12 pts received 4 cycles of full-dose 
epirubicin 120mg/m2 and Ifosfamide 9g/m2 and G-CSF; 2 pts 
3 cycles of weekly Taxol 80 mg/m2. All pts underwent RT, 
median dose 54Gy (45-59.4Gy). Only 1 pt had moderate acute 
pericarditis and 2 had late toxicity (mild ejection fraction 
reduction). 3 pts with major response to CT-RT underwent 
successful complete surgical resection. At a median follow-up 
of 40 months (12-137), 9pts are alive and 6 are disease-free. 
 
Conclusion: In our experience, RT for cardiac sarcomas 
appeared to be feasible, also when combined with CT and 
surgery. Technological advances in RT planning and delivery 
and further insight into RT cardiac tolerance are crucial in 
minimizing the risk of RIHD. Further experience is needed to 
confirm these encouraging results. 
 
 
 
 
 
